Many mental illnesses and disorders were long thought to begin only after childhood and adolescence. However, research in recent years has revealed that half of all lifetime mental illnesses begin by age 14. Despite the high number of children and adolescents having mental illness, fewer than one in five of affected children get the help they need. Due to the small pool of child and adolescent psychiatrists, psychologists, and other mental health professionals serving the 18 and under population—especially in rural areas—pediatricians, primary health physicians, and general practitioners are frequently being called upon to assess and treat young patients with even the most serious of the mental health disorders. However, a Canadian study found that most physicians did not have enough knowledge and support to detect and manage mental health conditions in pediatric patients.
If an examination rules out a physical condition, the physician must turn his or her attention to the child’s mental state. Distinguishing between normal developmental behavior from a true mental disorder can be difficult for even the seasoned child and adolescent psychiatrist. The pediatrician or primary care provider who has no psychiatrist in the area to whom to refer the young patient may be called upon to diagnose and treat a child with a constellation of symptoms that could be diagnosed as any or a number of disorders, such as conduct disorder, bipolar disorder, oppositional defiant disorder, attention-deficit/hyperactivity disorder, panic disorder, delinquency, borderline personality, or some other psychiatric condition sharing similar symptoms, all requiring different types of treatment.
Not only are personal relationships with family and friends affected by children with mental disorders, but proper psychological development of the child, performance at school, social integration, self-esteem, and ultimately functioning as a well-adjusted adult all depend upon proper mental health care while growing up. Youths with untreated mental illness often end up in the criminal justice system. In fact, nearly 60 percent of boys and girls involved in state and local juvenile justice systems throughout the country suffer from mental disorders, at least 20 percent of whom experience symptoms so severe that their ability to function is significantly impaired.
The diagnosis of mental disorders is not an exact science; diagnosis with absolute precision and certainty is impossible. It is that much harder in patients under 25. And with restrictions on many insurance companies as to the amount of time a mental health professional may spend examining a child for the purpose of making a diagnosis, many diagnoses and subsequent treatments are wrong and do more harm than good. For instance, many managed care companies offer a single one-hour diagnostic session with a child or adolescent psychiatrist or psychologist to determine a child or adolescent’s mental status. The American Academy of Child and Adolescent Psychiatry takes the position that such restrictions “are inadequate and may lead to insufficient information, condensed evaluations, diagnostic errors, and inadequate treatment planning.”
According to the Centers for Disease Control National Vital Statistics Report, suicide is the third leading cause of death among 15- to 24-year-olds (behind only accidents and homicides), and the sixth leading cause of death for five- to 14-year-olds. Although suicides account for only about 1.4 percent of all deaths in the United States annually, they comprise 12 percent of all deaths among 15 to 24-year-olds.
In 2007, the latest year for which data is available, there were approximately 4,030 suicides in youths between the ages of 15 and 24, and 195 suicides in children ages 5 to 14. Over 150,000 trips to U.S. emergency rooms are made each year after attempted suicides or other self-harm incidents among persons aged 10 to 24 years of age. Among young people ages 15 to 24 years old, there is one successful suicide for every 100-200 attempts. The most consistently reported pattern is that the risk of first onset for suicidal behavior increases significantly at the start of adolescence (12 years), peaks at 16 years, and remains elevated into the early 20s.
In one study, the researchers found that 14.5 percent of high school students reported having contemplated suicide in the previous 12 months, 11.3 percent had made a suicide plan, 6.9 percent reported that they had actually attempted suicide one or more times during the same period, and two percent had made a suicide attempt that resulted in an injury, poisoning, or an overdose that required medical attention.
Over 90 percent of attempted or completed suicide victims under 19 years of age have at least one psychiatric disorder, untreated depression being foremost among them. As many as one in 33 children and one in eight adolescents suffer from clinical depression, known in the mental health profession as major depressive disorder (MDD). Untreated depression is generally considered the third highest risk factor for suicide among youth, behind only previous suicide attempts and a history of suicide in the family, although some experts feel that untreated depression is the most common cause of suicide.
In children and adolescents, the symptoms of major depression are often different than those of adult depression. Some of the symptoms of a depressed child or adolescent are irritability, hostility, grumpiness, an easy loss of temper, poor school performance, persistent boredom, and risk taking (especially in depressed adolescents). Unexplained aches and pains are also common symptoms of depression in young people.
Since untreated depression is one of the leading causes of suicide in children, adolescents, and young adults, and depression is thought to be largely due to a “chemical imbalance” involving certain neurotransmitters in the brain (serotonin, norepinephrine, and dopamine), it is only natural that physicians would prescribe antidepressants to their depressed young patients as an integral part of their overall mental and physical health treatment plan, in addition to a course of psychotherapy and other treatments. In recognition of the fact that many attempted and completed child and adolescent suicides are due to underlying depression, from 1990 through 2003 the prescriptions for and use of antidepressants—in particular the “new” generation of antidepressants, “selective serotonin reuptake inhibitors” (SSRIs) such as Prozac, Paxil, and Zoloft, and the SSRI/norepinephrine reuptake inhibitor drug Effexor—by children, adolescents, and young adults had been rising significantly each year. During those years, the number of attempted and completed suicides in these age groups went down.
In October 2003, the FDA issued a Public Health Advisory warning that there is twice the risk (from 2 percent to 4 percent) in suicidal ideation and behavior in children under the age of 19 who were not actively suicidal when they are starting treatment with one of the newer antidepressants (sometimes as soon as 10 days after starting the antidepressant or when the dosage of the antidepressant is increased or decreased.)
A year later, in October 2004, the FDA issued another public health advisory requiring antidepressant manufacturers to include a “black box” warning in its prescribing information—the most serious action the FDA can take short of withdrawing approval of the drug (i.e., taking the drug off the market). The black box warning is required for all antidepressants—not just the SSRIs—regarding the risk of suicidality at certain times in pediatric patients being treated for depression. In May 2007, the FDA extended the warning to include the risk to young adults under 25.
After the FDA’s October 2003 Public Health Advisory, the overall rate of new depression diagnoses in patients 18 and under declined and the number of patients in this age group who were being prescribed the newer antidepressants decreased. The exception to this trend involved the number of patients in this age group who were prescribed fluoxetine (generic Prozac), the only antidepressant approved by the FDA for pediatric use.
Before 2003, SSRI prescriptions had steadily increased since 1987. Aside from minor fluctuations in 1993 (a one percent increase) and in 2000 (a three percent increase), the child and adolescent suicide rate consistently declined for the 15 years from 1988 to 2003. However, after the FDA’s 2003 public health advisory regarding several reports of children and adolescents taking antidepressants who attempted or committed suicide, the number of depressed youths being prescribed an antidepressant declined by some 20 percent, and in 2004 the suicide rate in U.S. adolescents increased by a record 14 percent from 2003. These increases in completed suicide occurred despite decreasing overall SSRI prescriptions among these age groups. Other countries, such as Canada and the Netherlands, reported similar increases in suicide among children, adolescents, and young adults when the number of prescriptions for SSRIs decreased.
The number of attempted and completed suicides among children and adolescents in the United States has increased since the black box warning was required. However, most completed suicides have no trace of an antidepressant in their system. In Canada, a similar lack of antidepressants in the systems of the “vast majority” of children and adolescents who had successfully completed suicide was found. As two psychiatrists pondered, “If SSRIs increase the risk of suicide, it is unclear why these drugs are so rarely found on toxicological examinations of youth after suicide.” Another study stated that if the FDA’s conclusion that there may be a causal link between suicide and antidepressants were correct, “we would have expected to see decreases in the suicide rate during the period of declining SSRI prescription rates, but instead we saw an increase in suicide rates, and the increase was greatest in the age range most affected by the decline in SSRI prescription rates. This finding suggests that SSRIs confer a protective effect.”
The new warning balances the efficacy of antidepressants in youthful patient against the risk of drug-induced-suicide. According to the black-box warning, such monitoring should include at least weekly face-to-face contact with patients or their family members or caregivers during the first four weeks of treatment, then biweekly visits for the next four weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may be appropriate between face-to-face visits. Clinical evidence, however, reveals that this observation regimen is not being adhered to.
During the 12-month period from August 2006 to July 2007, 62 percent of the total number of antidepressant prescriptions during the year were written by general practitioners, not psychiatrists. While pediatricians (who were included in the general practitioners category) prescribed 25 percent of all stimulants, they wrote prescriptions for only 21 percent of antidepressants during that time frame. The authors of one article concluded that, “[g]iven the large role of primary care providers in psychotropic drug prescribing, additional efforts may be needed to enhance the quality of psychiatric treatment in general practice settings across a range of psychiatric conditions.”
Because untreated depression is a leading cause of suicide in youth, pediatricians and other physicians who treat patients under 25 should routinely screen their young patients for this debilitating, life-threatening condition. The health care provider should also inquire into the medical and psychiatric history of the patient’s parents, specifically asking about whether a parent suffered from depression, committed suicide, or sexually abused the patient, as these are increased markers for a suicide attempt by the young patient.
If a child or adolescent patient is diagnosed with major depression, and the health care provider is reluctant to prescribe antidepressants for fear of the increase in suicidal thinking and behavior, the health care provider must provide alternative and approved methods of treatment or refer the patient to another health care provider who will provide appropriate treatment, whether it be in the form of prescribing psychotropic medication or employing regular psychotherapy sessions. Two particular forms of psychotherapy have been shown to be helpful in treating depressed patients. One is cognitive behavioral therapy, which helps the patient learn new ways of thinking and behaving. The other is interpersonal therapy, which helps patients understand and work through troubled personal relationships. Some health care providers are prescribing newer atypical antipsychotics (e.g., Abilify, Risperdal, and Seroquel) and other non-antidepressant psychoactive drugs in place of antidepressants, often with a less than efficacious result and a higher risk of side effects than the newer generation of antidepressants.
In seriously depressed youths, a major study sponsored by the National Institute of Mental Health involving adolescents having a mean age of 15 found that, after 12 weeks, the most effective treatment for adolescents with major depression was a combination of fluoxetine (Prozac) and Cognitive-Behavioral Therapy (CBT), rather than either one alone or placebo.
It is clear that compared to placebo the overall benefits of the newer antidepressants are successful in treating major depression in children, adolescents, and young adults and in reducing the risk of completed suicide. Although there may be a higher risk of suicidal thoughts and behavior at certain times, the health care provider can minimize the risk with proper monitoring of the patient. Deliberately not diagnosing major depression in pediatric patients to avoid the antidepressant-suicide issue can only lead to untreated depression and a much higher risk of completed suicides.
As two psychiatrists wrote, two facts are undisputed: (1) pediatric suicide is most common in children with untreated major depression, and (2) SSRIs are rarely found to be present at the time of death in suicide victims, suggesting that SSRIs are not likely to be a causal factor in a substantial proportion of child and adolescent suicide. These writers further state:
If the intent of the pediatric black box warning was to save lives, the warning failed, and in fact may have had the opposite effect; more children and adolescents have committed suicide since it was introduced. If the FDA’s goal is to ensure that children and adults treated with antidepressants receive adequate follow-up care to better detect and treat emergent suicidal thoughts, the current black box warning is not a useful approach; what should be considered instead is better education and training of physicians.
Major depression in a child, teenager, or young adult is a serious mental health disorder that if left untreated or inadequately treated can lead to the youth’s isolation, anhedonia, risk taking, change in personality, inability to tend to his or her basic personal hygiene, suicidal thoughts and attempts, and, in the worst cases, completed suicide. Mental health care providers who diagnose (or should have diagnosed) a child, adolescent, or young adult patient with major depressive disorder must weigh the pros of prescribing antidepressants and their attendant risks against the cons of not prescribing such drugs and using other forms of treatment. However, health care providers cannot simply ignore major depression in a young patient and do nothing because of the increased risk of suicide inherent in untreated depression.
If your child has been acting strangely lately—e.g., an outgoing child becoming more introverted and keeping to himself, getting into trouble at school, grades dropping, listening to songs about death, suicide, or there being “only one way out,” or repeatedly playing songs by rock stars such as Kurt Cobain (the leader of the band Nirvana, who killed himself with a shotgun while at the top of his popularity)—you should immediately get the child to a mental health professional for an examination and evaluation.
